NCT03752541View on ClinicalTrials.gov

Efficacy and Safety Evaluation of BCMA-UCART

NASuspendedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

March 20, 2023

Study Completion Date

November 20, 2023

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

BCMA-UCART

A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.

Trial Locations (1)

200065

Shanghai Tongji Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai Tongji Hospital, Tongji University School of Medicine

OTHER

collaborator

Second Xiangya Hospital of Central South University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT03752541 - Efficacy and Safety Evaluation of BCMA-UCART | Biotech Hunter | Biotech Hunter